pumecitinib vs Ruxolitinib (Opzelura)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline

pumecitinib

Developed by Prime Gene Therapeutics and partners

Phase 3 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Ruxolitinib (Opzelura)

Marketed by Incyte and partners

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT03745638 · Phase 3 · completed

This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.

Next expected readout: August 2027 · NCT07661979 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) (met)

Result source: NCT03745638

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointpumecitinibRuxolitinib (Opzelura)
EASI-75—Trial running · NCT0658768570% vs 18.5%+51.5 vs placebo1.5% · wk 8 · n 160NCT06238817
21 other results
  • 56% vs 24.6% 0.75% Cream BID · wk 8 · n 252 · Phase 3 · secondary NCT03745638
  • 62.1% vs 24.6% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 51.5% vs 14.4% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 61.8% vs 14.4% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 51.5% vs 15.4% 0.75% Cream BID · wk 8 · n 134 · Phase 3 · secondary NCT04921969
  • 67.2% vs 15.4% 1.5% Cream BID · wk 8 · n 131 · Phase 3 · secondary NCT04921969
  • 51.6% vs 14.3% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 58.5% vs 14.3% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 42% vs 10.2% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 50.4% vs 10.2% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 53% vs 12.3% 0.75% Cream BID · wk 4 · n 134 · Phase 3 · secondary NCT04921969
  • 62.6% vs 12.3% 1.5% Cream BID · wk 4 · n 131 · Phase 3 · secondary NCT04921969
  • 30.2% vs 5.6% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 36% vs 5.6% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 4.2% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 31.6% vs 4.2% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • 35.8% vs 6.2% 0.75% Cream BID · wk 2 · n 134 · Phase 3 · secondary NCT04921969
  • 43.5% vs 6.2% 1.5% Cream BID · wk 2 · n 131 · Phase 3 · secondary NCT04921969
  • 33.3% vs 35.3% 1.5% BID · wk 8 · n 48 · Phase 2 · secondary NCT05127421
  • 29.2% vs 33.3% 1.5% BID · wk 4 · n 48 · Phase 2 · secondary NCT05127421
  • 10.4% vs 5.6% 1.5% BID · wk 2 · n 48 · Phase 2 · secondary NCT05127421
IGA 0/1 with 2-point improvement—Trial running · NCT0658768515.7% vs 9.6%+6.1 vs placebo0.15% QD · wk 8 · n 51NCT03011892
11 other results
  • 31.4% vs 9.6% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • 30.8% vs 9.6% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • 48% vs 9.6% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • 9.8% vs 7.7% 0.15% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 13.7% vs 7.7% 0.5% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 21.2% vs 7.7% 1.5% QD · wk 4 · n 52 · Phase 2 · secondary NCT03011892
  • 38% vs 7.7% 1.5% BID · wk 4 · n 50 · Phase 2 · secondary NCT03011892
  • 5.9% vs 1.9% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 4.1% vs 1.9% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 13.5% vs 1.9% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • 8% vs 1.9% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
EASI-90—Trial running · NCT0658768538.1% vs 9.5%+28.6 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
11 other results
  • 44.3% vs 9.5% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 35.1% vs 4.2% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 43.4% vs 4.2% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 30.6% vs 4% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 36.4% vs 4% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 2.5% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 32.5% vs 2.5% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 12.7% vs 2.4% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 19.8% vs 2.4% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 10.8% vs 0.8% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 15.8% vs 0.8% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
EASI, % change—Trial running · NCT06587685-71.0% vs -37.9%−33.1 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
31 other results
  • -77.4% vs -37.9% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • -73.4% vs -28.8% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • -74.8% vs -28.8% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • -68.0% vs -23.0% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • -71.1% vs -23.0% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • -65% vs -20.4% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • -66.3% vs -20.4% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • -51.8% vs -16.3% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • -56.6% vs -16.3% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • -45.9% vs -13.9% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • -49.1% vs -13.9% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • -71.6% vs -11.9% 1.5% BID · wk 4 · n 49 · Phase 2 · primary NCT03011892
  • -50.2% vs -21.9% 0.15% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -58.4% vs -21.9% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -67.0% vs -21.9% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • -79.0% vs -21.9% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -11.9% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -11.9% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -11.9% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -45.4% vs -15.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.2% vs -15.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -67% vs -15.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -15.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -30.0% vs -4.8% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -45.9% vs -4.8% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -49.9% vs -4.8% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • -52.7% vs -4.8% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -59.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -59.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -59.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -59.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892

EASI-75

pumecitinib
—Trial running · NCT06587685
Ruxolitinib (Opzelura)
70% vs 18.5%+51.5 vs placebo1.5% · wk 8 · n 160NCT06238817
21 other results
  • 56% vs 24.6% 0.75% Cream BID · wk 8 · n 252 · Phase 3 · secondary NCT03745638
  • 62.1% vs 24.6% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 51.5% vs 14.4% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 61.8% vs 14.4% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 51.5% vs 15.4% 0.75% Cream BID · wk 8 · n 134 · Phase 3 · secondary NCT04921969
  • 67.2% vs 15.4% 1.5% Cream BID · wk 8 · n 131 · Phase 3 · secondary NCT04921969
  • 51.6% vs 14.3% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 58.5% vs 14.3% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 42% vs 10.2% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 50.4% vs 10.2% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 53% vs 12.3% 0.75% Cream BID · wk 4 · n 134 · Phase 3 · secondary NCT04921969
  • 62.6% vs 12.3% 1.5% Cream BID · wk 4 · n 131 · Phase 3 · secondary NCT04921969
  • 30.2% vs 5.6% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 36% vs 5.6% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 4.2% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 31.6% vs 4.2% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • 35.8% vs 6.2% 0.75% Cream BID · wk 2 · n 134 · Phase 3 · secondary NCT04921969
  • 43.5% vs 6.2% 1.5% Cream BID · wk 2 · n 131 · Phase 3 · secondary NCT04921969
  • 33.3% vs 35.3% 1.5% BID · wk 8 · n 48 · Phase 2 · secondary NCT05127421
  • 29.2% vs 33.3% 1.5% BID · wk 4 · n 48 · Phase 2 · secondary NCT05127421
  • 10.4% vs 5.6% 1.5% BID · wk 2 · n 48 · Phase 2 · secondary NCT05127421

IGA 0/1 with 2-point improvement

pumecitinib
—Trial running · NCT06587685
Ruxolitinib (Opzelura)
15.7% vs 9.6%+6.1 vs placebo0.15% QD · wk 8 · n 51NCT03011892
11 other results
  • 31.4% vs 9.6% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • 30.8% vs 9.6% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • 48% vs 9.6% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • 9.8% vs 7.7% 0.15% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 13.7% vs 7.7% 0.5% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 21.2% vs 7.7% 1.5% QD · wk 4 · n 52 · Phase 2 · secondary NCT03011892
  • 38% vs 7.7% 1.5% BID · wk 4 · n 50 · Phase 2 · secondary NCT03011892
  • 5.9% vs 1.9% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 4.1% vs 1.9% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 13.5% vs 1.9% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • 8% vs 1.9% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892

EASI-90

pumecitinib
—Trial running · NCT06587685
Ruxolitinib (Opzelura)
38.1% vs 9.5%+28.6 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
11 other results
  • 44.3% vs 9.5% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 35.1% vs 4.2% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 43.4% vs 4.2% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 30.6% vs 4% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 36.4% vs 4% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 2.5% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 32.5% vs 2.5% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 12.7% vs 2.4% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 19.8% vs 2.4% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 10.8% vs 0.8% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 15.8% vs 0.8% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651

EASI, % change

pumecitinib
—Trial running · NCT06587685
Ruxolitinib (Opzelura)
-71.0% vs -37.9%−33.1 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
31 other results
  • -77.4% vs -37.9% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • -73.4% vs -28.8% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • -74.8% vs -28.8% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • -68.0% vs -23.0% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • -71.1% vs -23.0% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • -65% vs -20.4% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • -66.3% vs -20.4% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • -51.8% vs -16.3% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • -56.6% vs -16.3% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • -45.9% vs -13.9% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • -49.1% vs -13.9% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • -71.6% vs -11.9% 1.5% BID · wk 4 · n 49 · Phase 2 · primary NCT03011892
  • -50.2% vs -21.9% 0.15% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -58.4% vs -21.9% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -67.0% vs -21.9% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • -79.0% vs -21.9% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -11.9% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -11.9% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -11.9% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -45.4% vs -15.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.2% vs -15.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -67% vs -15.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -15.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -30.0% vs -4.8% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -45.9% vs -4.8% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -49.9% vs -4.8% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • -52.7% vs -4.8% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -59.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -59.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -59.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -59.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

pumecitinib: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. pumecitinib: 0 of 4 rows · Ruxolitinib (Opzelura): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRuxolitinib (Opzelura)
Dropout rate
—0.75% Creama
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.9%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.1%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.7%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.7%1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
10.4%0.75% Cream BID
NCT04921969 · Phase 3
12.2%1.5% Cream BID
NCT04921969 · Phase 3
3.1%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
11.1%1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
10.2%1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
13.7%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
10%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
13.5%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—0.75% Creama
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
0.7%0.75% Cream BID
NCT04921969 · Phase 3
0.8%1.5% Cream BID
NCT04921969 · Phase 3
0%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
0%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Serious AEs
—0.75% Creama
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.7%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.3%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9%1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
0%0.75% Cream BID
NCT04921969 · Phase 3
1.9%1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
2%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
0%1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
0.75% Cream BIDa
upper respiratory tract infection 9% (placebo 3.2%)
nasopharyngitis 6% (placebo 1.6%)
headache 3.7% (placebo 4%)
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 13 more results
1.5% Cream BID
upper respiratory tract infection 12% (placebo 3.2%)
nasopharyngitis 10.3% (placebo 1.6%)
headache 5.3% (placebo 4%)
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.75% cream BID
nasopharyngitis 9.3% (placebo 0%)
upper respiratory tract infection 7.6% (placebo 0.8%)
application site pain 0.7% (placebo 6.5%)
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.5% cream BID
nasopharyngitis 9.1% (placebo 0%)
upper respiratory tract infection 7.7% (placebo 0.8%)
application site pain 0.7% (placebo 6.5%)
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.5% Cream BID
upper respiratory tract infection 10.7%
nasopharyngitis 8.7%
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.75% Cream BID
upper respiratory tract infection 13.8% (placebo 3.1%)
covid-19 8.2% (placebo 1.5%)
pyrexia 6.3% (placebo 0%)
NCT04921969 · Phase 3
1.5% Cream BID
upper respiratory tract infection 14.9% (placebo 3.1%)
nasopharyngitis 13% (placebo 1.5%)
covid-19 7.1% (placebo 1.5%)
NCT04921969 · Phase 3
1.5%
upper respiratory tract infection 10.3% (placebo 4.9%)
nasopharyngitis 5.9% (placebo 4.9%)
application site pain 1% (placebo 6.2%)
NCT06238817 · Phase 3 · registry result, not featured evidence
1.5% BID
application site reaction 1.4% (placebo 8.7%)
NCT05127421 · Phase 2 · registry result, not featured evidence
1.5% Cream BID
covid-19 6.1%
back pain 4.1%
headache 4.1%
NCT04839380 · Phase 2 · registry result, not featured evidence
0.15% QD
nasopharyngitis 5.9% (placebo 7.7%)
upper respiratory tract infection 3.9% (placebo 5.8%)
dermatitis atopic 2% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
0.5% QD
nasopharyngitis 2% (placebo 7.7%)
upper respiratory tract infection 2% (placebo 5.8%)
dermatitis atopic 0% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
1.5% BID
nasopharyngitis 5% (placebo 7.7%)
upper respiratory tract infection 2.7% (placebo 5.8%)
dermatitis atopic 1.5% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
1.5% QD
nasopharyngitis 7.8% (placebo 7.7%)
dermatitis atopic 3.9% (placebo 7.7%)
upper respiratory tract infection 2% (placebo 5.8%)
NCT03011892 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ruxolitinib (Opzelura)

IGA-TS 50% (n=252) vs 15.1% (n=126) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
53.8% (n=253) vs 15.1% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
22.2% (n=252) vs 3.2% (n=126) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.3% (n=253) vs 3.2% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
42.5% (n=252) vs 6.3% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
46.6% (n=253) vs 6.3% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
39% (n=231) vs 7.6% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.3% (n=228) vs 7.6% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
17.3% (n=231) vs 4.2% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25% (n=228) vs 4.2% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.5% (n=231) vs 5.9% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
43.4% (n=228) vs 5.9% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
36.6% (n=134) vs 10.8% (n=65) placebo @ 8wk0.75% Cream BID
NCT04921969 · Phase 3
56.5% (n=131) vs 10.8% (n=65) placebo @ 8wk1.5% Cream BID
NCT04921969 · Phase 3
24.6% (n=134) vs 4.6% (n=65) placebo @ 2wk0.75% Cream BID
NCT04921969 · Phase 3
35.1% (n=131) vs 4.6% (n=65) placebo @ 2wk1.5% Cream BID
NCT04921969 · Phase 3
36.6% (n=134) vs 12.3% (n=65) placebo @ 4wk0.75% Cream BID
NCT04921969 · Phase 3
48.1% (n=131) vs 12.3% (n=65) placebo @ 4wk1.5% Cream BID
NCT04921969 · Phase 3
EASI-75 56% (n=252) vs 24.6% (n=126) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 21 more results
62.1% (n=253) vs 24.6% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
30.2% (n=252) vs 5.6% (n=126) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
36% (n=253) vs 5.6% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.6% (n=252) vs 14.3% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
58.5% (n=253) vs 14.3% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.5% (n=231) vs 14.4% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
61.8% (n=228) vs 14.4% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25.5% (n=231) vs 4.2% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
31.6% (n=228) vs 4.2% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
42% (n=231) vs 10.2% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
50.4% (n=228) vs 10.2% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.8% (n=134) vs 6.2% (n=65) placebo @ 2wk0.75% Cream BID
NCT04921969 · Phase 3
43.5% (n=131) vs 6.2% (n=65) placebo @ 2wk1.5% Cream BID
NCT04921969 · Phase 3
53% (n=134) vs 12.3% (n=65) placebo @ 4wk0.75% Cream BID
NCT04921969 · Phase 3
62.6% (n=131) vs 12.3% (n=65) placebo @ 4wk1.5% Cream BID
NCT04921969 · Phase 3
51.5% (n=134) vs 15.4% (n=65) placebo @ 8wk0.75% Cream BID
NCT04921969 · Phase 3
67.2% (n=131) vs 15.4% (n=65) placebo @ 8wk1.5% Cream BID
NCT04921969 · Phase 3
70% (n=160) vs 18.5% (n=81) placebo @ 8wk1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
10.4% (n=48) vs 5.6% (n=18) placebo @ 2wk1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
29.2% (n=48) vs 33.3% (n=18) placebo @ 4wk1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
33.3% (n=48) vs 35.3% (n=18) placebo @ 8wk1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
Itch NRS 4-Point Improvement 40.4% (n=156) vs 15.4% (n=78) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
52.2% (n=161) vs 15.4% (n=78) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
26.3% (n=156) vs 5.1% (n=78) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.5% (n=161) vs 5.1% (n=78) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.5% (n=156) vs 11.5% (n=78) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.6% (n=161) vs 11.5% (n=78) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Sleep Disturbance 6-Point Improvement 21% (n=233) vs 9.5% (n=116) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
22.3% (n=238) vs 9.5% (n=116) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.7% (n=233) vs 5.2% (n=116) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
14.7% (n=238) vs 5.2% (n=116) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
19.3% (n=233) vs 6.9% (n=116) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21% (n=238) vs 6.9% (n=116) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Sleep-Related Impairment 6-Point Improvement 20.2% (n=233) vs 13.2% (n=114) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
21.6% (n=245) vs 13.2% (n=114) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
16.3% (n=233) vs 8.8% (n=114) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.5% (n=245) vs 8.8% (n=114) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
20.6% (n=233) vs 13.2% (n=114) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
19.2% (n=245) vs 13.2% (n=114) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA 0/1 32.5% (n=252) vs 6.3% (n=126) placebo @ 2wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
34.8% (n=253) vs 6.3% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
53.2% (n=252) vs 15.1% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
54.9% (n=253) vs 15.1% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
58.7% (n=252) vs 23.8% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
62.8% (n=253) vs 23.8% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
24.2% (n=231) vs 9.3% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
34.6% (n=228) vs 9.3% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
45.9% (n=231) vs 16.9% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
52.6% (n=228) vs 16.9% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.1% (n=231) vs 16.1% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
62.3% (n=228) vs 16.1% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
61.3% (n=160) vs 13.6% (n=81) placebo @ 8wk1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
IGA 0/1 65.3% (n=222) @ 8wk0.75% Cream
responder rate · % of participants
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 71 more results
68.4% (n=225) @ 8wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
62.7% (n=222) @ 12wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
66.5% (n=225) @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
66.5% (n=222) @ 16wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
68.9% (n=225) @ 16wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
62.4% (n=222) @ 20wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.5% (n=225) @ 20wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
67% (n=222) @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.7% (n=225) @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
67.3% (n=222) @ 28wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.3% (n=225) @ 28wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71.5% (n=222) @ 32wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.9% (n=225) @ 32wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.5% (n=222) @ 36wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71.7% (n=225) @ 36wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.5% (n=222) @ 40wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.5% (n=225) @ 40wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.3% (n=222) @ 44wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.2% (n=225) @ 44wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.3% (n=222) @ 48wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.8% (n=225) @ 48wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.9% (n=222) @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.4% (n=225) @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
26% (n=50) @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.2% (n=49) @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
57.5% (n=187) @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
65.5% (n=203) @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
59.6% (n=50) @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
45.8% (n=49) @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
59.6% (n=187) @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73% (n=203) @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
59.6% (n=50) @ 16wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
59.6% (n=49) @ 16wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
68.9% (n=187) @ 16wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.1% (n=203) @ 16wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69% (n=50) @ 20wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
58.7% (n=49) @ 20wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71.1% (n=187) @ 20wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.5% (n=203) @ 20wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
61% (n=50) @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
67.4% (n=49) @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
70.4% (n=187) @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
72.4% (n=203) @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
67.6% (n=50) @ 28wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
67.4% (n=49) @ 28wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.1% (n=187) @ 28wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
72% (n=203) @ 28wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.1% (n=50) @ 32wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
72.7% (n=49) @ 32wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.2% (n=187) @ 32wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.8% (n=203) @ 32wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
81.3% (n=50) @ 36wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.8% (n=49) @ 36wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
73.3% (n=187) @ 36wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
79.3% (n=203) @ 36wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.1% (n=50) @ 40wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
66.7% (n=49) @ 40wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76% (n=187) @ 40wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
79.3% (n=203) @ 40wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.3% (n=50) @ 44wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
70.5% (n=49) @ 44wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.2% (n=187) @ 44wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
80.1% (n=203) @ 44wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
79.4% (n=50) @ 48wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.8% (n=49) @ 48wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.2% (n=187) @ 48wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.9% (n=203) @ 48wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
79.4% (n=50) @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
74.4% (n=49) @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
76.7% (n=187) @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
80.1% (n=203) @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EASI-50 53.2% (n=252) vs 19.8% (n=126) placebo @ 2wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 23 more results
62.5% (n=253) vs 19.8% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
68.7% (n=252) vs 27.8% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.5% (n=253) vs 27.8% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.4% (n=252) vs 43.7% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.9% (n=253) vs 43.7% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
45.5% (n=231) vs 16.1% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
53.5% (n=228) vs 16.1% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.7% (n=231) vs 28.8% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
71.9% (n=228) vs 28.8% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
75.8% (n=231) vs 33.9% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
79.8% (n=228) vs 33.9% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
31.4% (n=51) vs 13.5% (n=52) placebo @ 2wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
57.1% (n=51) vs 13.5% (n=52) placebo @ 2wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
50% (n=52) vs 13.5% (n=52) placebo @ 2wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
52% (n=50) vs 13.5% (n=52) placebo @ 2wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
52.9% (n=51) vs 23.1% (n=52) placebo @ 4wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
58.8% (n=51) vs 23.1% (n=52) placebo @ 4wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
73.1% (n=52) vs 23.1% (n=52) placebo @ 4wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
78% (n=50) vs 23.1% (n=52) placebo @ 4wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
54.9% (n=51) vs 26.9% (n=52) placebo @ 8wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
62.7% (n=51) vs 26.9% (n=52) placebo @ 8wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
69.2% (n=52) vs 26.9% (n=52) placebo @ 8wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
76% (n=50) vs 26.9% (n=52) placebo @ 8wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
EASI-90 12.7% (n=252) vs 2.4% (n=126) placebo @ 2wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 11 more results
19.8% (n=253) vs 2.4% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
30.6% (n=252) vs 4% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
36.4% (n=253) vs 4% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.1% (n=252) vs 9.5% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
44.3% (n=253) vs 9.5% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.8% (n=231) vs 0.8% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.8% (n=228) vs 0.8% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25.5% (n=231) vs 2.5% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
32.5% (n=228) vs 2.5% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.1% (n=231) vs 4.2% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
43.4% (n=228) vs 4.2% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EASI -51.82% (n=252) vs -16.34% (n=126) placebo @ 2wk0.75% Cream BID
percent change · % of baseline
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 31 more results
-56.62% (n=253) vs -16.34% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-68.04% (n=252) vs -23.03% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-71.08% (n=253) vs -23.03% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-71.01% (n=252) vs -37.88% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-77.4% (n=253) vs -37.88% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-45.86% (n=231) vs -13.95% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-49.08% (n=228) vs -13.95% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-65% (n=231) vs -20.45% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-66.35% (n=228) vs -20.45% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-73.37% (n=231) vs -28.84% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-74.84% (n=228) vs -28.84% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-71.57% (n=49) vs -11.9% (n=44) placebo @ 4wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-44.92% (n=47) vs -11.9% (n=44) placebo @ 4wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-52.8% (n=47) vs -11.9% (n=44) placebo @ 4wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-66.72% (n=49) vs -11.9% (n=44) placebo @ 4wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-44.92% (n=47) vs -59.54% (n=46) TAC @ 4wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-52.8% (n=47) vs -59.54% (n=46) TAC @ 4wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-66.72% (n=49) vs -59.54% (n=46) TAC @ 4wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-71.57% (n=49) vs -59.54% (n=46) TAC @ 4wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-29.96% (n=51) vs -4.84% (n=52) placebo @ 2wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-45.88% (n=51) vs -4.84% (n=52) placebo @ 2wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-49.88% (n=52) vs -4.84% (n=52) placebo @ 2wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-52.68% (n=50) vs -4.84% (n=52) placebo @ 2wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-50.24% (n=51) vs -21.86% (n=52) placebo @ 8wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-58.37% (n=51) vs -21.86% (n=52) placebo @ 8wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-67.05% (n=52) vs -21.86% (n=52) placebo @ 8wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-79.01% (n=50) vs -21.86% (n=52) placebo @ 8wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-45.4% (n=47) vs -15.5% (n=44) placebo @ 4wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-52.2% (n=47) vs -15.5% (n=44) placebo @ 4wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-67% (n=49) vs -15.5% (n=44) placebo @ 4wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-71.6% (n=49) vs -15.5% (n=44) placebo @ 4wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
SCORAD -43.96% (n=252) vs -16.67% (n=126) placebo @ 2wk0.75% Cream BID
percent change · % of baseline
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 11 more results
-49.32% (n=253) vs -16.67% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-57.8% (n=252) vs -27.68% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-61.33% (n=253) vs -27.68% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-62.14% (n=252) vs -37% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-67.24% (n=253) vs -37% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-39.62% (n=231) vs -13.87% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-45.22% (n=228) vs -13.87% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-54.85% (n=231) vs -21.79% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-58.76% (n=228) vs -21.79% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-63.71% (n=231) vs -23.63% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-67.39% (n=228) vs -23.63% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Itch NRS -2.28 vs -0.89 placebo score @ 2wk0.75% Cream BID
absolute change · score
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 23 more results
-2.53 vs -0.89 placebo score @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.79 vs -1.08 placebo score @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.16 vs -1.08 placebo score @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.14 vs -1.54 placebo score @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.53 vs -1.54 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.21 vs -0.69 placebo score @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.43 vs -0.69 placebo score @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.82 vs -1.03 placebo score @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3 vs -1.03 placebo score @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.28 vs -1.39 placebo score @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.09 vs -1.39 placebo score @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.9 vs -0.7 placebo score @ 2wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-2.5 vs -0.7 placebo score @ 2wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-3.1 vs -0.7 placebo score @ 2wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-3.7 vs -0.7 placebo score @ 2wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-2.3 vs -1 placebo score @ 4wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-2.6 vs -1 placebo score @ 4wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-3.3 vs -1 placebo score @ 4wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-4 vs -1 placebo score @ 4wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
-3 vs -1.2 placebo score @ 8wk0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-2.9 vs -1.2 placebo score @ 8wk0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-3.8 vs -1.2 placebo score @ 8wk1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
-4.2 vs -1.2 placebo score @ 8wk1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence

+ 57 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pumecitinib's landscape · Ruxolitinib (Opzelura)'s landscape